1. No category

MURRAY N. EHRINPREIS, M.D.
OFFICE
Division of Gastroenterology
Harper Hospital
3990 John R
Detroit, Michigan 48201
Telephone: (313) 745-8601
EDUCATION:
1964 - 1968
BA Degree, University of Michigan, Ann Arbor, MI
1968 - 1972
MD Degree, New York University School of Medicine, New York, NY
TRAINING:
1972 - 1973
Medical Intern, Bronx Municipal Hospital Center, Bronx, NY
1973 - 1975
Medical Resident, Bronx Municipal Hospital Center, Bronx, NY
1975 - 1977
Fellow in Gastroenterology, Albert Einstein College of Medicine,
Bronx, NY
FACULTY APPOINTMENTS:
1977 - 1990
Assistant Professor of Medicine, Division of Gastroenterology,
Wayne State University School of Medicine, Detroit, MI
1978 - 1979
Acting Chief, Division of Gastroenterology, Wayne State University
School of Medicine, Detroit, MI
1987 – 2000
Director of Clinical Education, Division of Gastroenterology, Wayne
State University School of Medicine, Detroit, MI
2000 - present
Fellowship Director, Division of Gastroenterology, Wayne State
University School of Medicine, Detroit, MI
1990 - 2000
Associate Professor (Clinician-Educator) of Medicine, Division of
Gastroenterology, Wayne State University School of Medicine,
Detroit, MI
2000 - present
Professor (Clinician-Educator) of Medicine, Division of
Gastroenterology, Wayne State University School of Medicine,
Detroit, MI
2
HOSPITAL OR OTHER PROFESSIONAL APPOINTMENTS:
1983 – 2002 Director of Nutritional Support Services, Harper-Grace Hospitals, Harper
Division, Detroit, MI
1978 - 1979
1990 - 1991
Interim Chief, Section of Gastroenterology Harper-Grace
Hospitals, Detroit, MI
1990 - 1991
Interim Director, Division of Gastroenterology, Wayne State
University School of Medicine, Detroit, Michigan
MAJOR PROFESSIONAL SOCIETIES:
American Association for the Study of Liver Disease
American Federation for Clinical Research
American Gastroenterological Association
American Society for Parenteral and Enteral Nutrition
American College of Gastroenterology, Fellow; Board of Governors Member
from MI 1992-1998; Ad Hoc Committee on Training 2003
American Society for Gastrointestinal Endoscopy
Midwest Gut Club
Detroit Gastroenterological Society; President 1985-1986
Michigan Society for Gastrointestinal Endoscopy; Secretary-Treasurer
1992-1994; President 1996-1998; Board Member 1992-1999
Michigan Society for Parenteral and Enteral Nutrition, Program Committee
LICENSURE & BOARD CERTIFICATION:
Licensure - Michigan
1975 - Diplomate, American Board of Internal Medicine
1977 - Diplomate, American Board of Gastroenterology
HONORS AND AWARDS:
Phi Beta Kappa - University of Michigan
College Teaching Award - Wayne State University, 1998
College Teaching Award – Wayne State University, 2001
SERVICE:
Patient Care:
Active Attending and consulting gastroenterology practice with University Internal
Medicine Specialists in the Harper Professional Bldg., Harper University Hospital
and Detroit Receiving Hospital. Active GI endoscopic practice. Outpatient total
parenteral nutrition management.
3
Professional Consultation:
Public Media Presentation (TV) Health Matters, Channel 56, "Beating
Digestive Disorders", February 17, 1994.
Public Media Presentation (Radio) WWJ, “Hepatitis”, February 1997.
Interview on “Gastroesophageal Reflux Disease” in Michigan
Chronicle, February 2001.
Interview on “Capsule Endoscopy” on the Dr. Jimmy Womack
Show, WGPR (Radio), December 5, 2004.
1985 - Present
Presentations to local and regional bodies (See
Presentations).
1977 - present
Gastroenterology Consultation Attending, Harper Hospital (3 - 4
months per year)
1977 - present
Gastroenterology Consultation Attending, Detroit Receiving
Hospital, (3 - 4 months)
1977 - present
Gastroenterology Consultant, Grace Hospital
1977 - present
Gastroenterology Consultant, Detroit Rehabilitation Institute
1977 – 1998
Gastroenterology Consultant, Veterans Affairs Medical Center, Allen
Park and Detroit
1979 - present
Medical Nutritional Support Services Attending, Harper Hospital
(4 months per year)
Editorial Activity:
Reviewer American Journal of Gastroenterology
Reviewer Gastroenterology
Reviewer New England Journal of Medicine
Book Reviewer New England Journal of Medicine
Reviewer Journal of Clinical Outcomes Management
Reviewer Journal of the Neurological Sciences
Reviewer American Journal of the Medical Sciences
Reviewer Drugs (Adis Drug Evaluation)
4
SERVICE (Cont.):
Boards & Committees
(Also see Professional Societies)
Medical School Committees:
1996 - 1997
Wayne State University School of Medicine, Department of
Biochemistry Internal Review Committee
Departmental Committees:
1984 - 1991
Treasurer, Board of Trustees, University Internists, P.C., (School of
Medicine Clinical Practice Group)
1984
DMCIOAD Board of Trustees
1984 - 1985
Liaison Committee for Medical Education
1987
Ad Hoc Department of Internal Medicine Internal Review Committee
(Reviewer - Practice Plan)
1991 - 1995
Operations Committee, Affiliated Internists (Dept. of Medicine Clinical
Practice Group)
1992 - present
Risk Management Committee, Affiliated Internists
1993 – 1997
Merit and Compensation Committee, Affiliated Internists
1996 – 1998
Board of Directors, Affiliated Internists
2000 - present
Protected Time Committee
2001- present
Research Committee
2001- 2004
Compliance Committee
2002- present
Merit and Compensation Committee
2003-present
Residency Operations Committee
2004-present
Ambulatory Practice Advisory Committee
5
Hospital Committees:
1983 - 1984
Medical Advisory Board, Harper-Grace Hospitals
1980 - 1985
Nutrition Committee, Harper Hospital
1979 - 1986
Quality Assurance Committee, Harper Hospital
2001- 2003
Medical Advisory Board, Harper University Hospital
1979 - present
Endoscopy Committee, Harper Hospital (Chairman,
1986-present)
1989 - present
Harper-Grace-Hutzel Diet Manual Committee, Chairman
1991 - present
Nutrition Advisory Committee, Harper Hospital, Chairman
1993 - present
Quality Enhancement and Clinical Resource Management
Committee
2000 - present
Chairman, Board of Trustees, Harper Medical Staff Trust Fund
TEACHING:
Wayne State University Faculty since 1977
1977 - 1998
Medicine Attending, Wayne State University School of Medicine,
Department of Medicine (1 - 4 months per year)
1978 - 1991
Coordinator, Weekly Gastroenterology Clinical Conference
(Continuing Medical Education Accredited)
1978 - 1991
Coordinator, Weekly Gastroenterology Basic Science Conference
(Continuing Medical Education Accredited)
1978 - present
Clinical Coordinator, Year I GI Physiology
1978 - 1988
Lecturer Year I GI Physiology
1984 - present
Coordinator, Year II GI Pathophysiology Course
1978 - present
Lecturer, Year II GI Pathophysiology Course
1978 - present
Coordinator, Year III GI Teaching Program
1978 – 1997
Lecturer, Year III GI Teaching Program (quarterly)
1983 - 1991
Coordinator, Weekly GI Journal Club
6
1984 - 1990
Attending, GI Medical Subspecialty Rotation, Wayne State
University School of Medicine - Harper Hospital (2 - 3 months per
year)
1986 – 2000
Director of Clinical Education, Division of Gastroenterology, Wayne
State University
1986 - 1988
Lecturer, Wayne State University Dept. of Medicine Board Review
Course
1987 – 1998
Lecturer, Wayne State University School of Pharmacy, Pharm D
Students
1989 - present
Medicine Residency Curriculum Committee, Wayne State
University
1996 - present
Lecturer and GI Course Coordinator, Wayne State University
Physicians Assistant Training Program
2003 - present
Lecturer, Wayne State University Year I Physiology
2005-present
Lecturer, Wayne State University, Graduate Students and Nurse
Clinicians Pathophysiology
GRANT SUPPORT:
1983
Ortho Pharmaceutical Corporation, "Effect of Etintidine in the Short-Term
Treatment of Duodenal Ulcer Disease Protocol # C82-061/062. 7/83-7/85.
Funded for $10,500. Principal Investigator.
1987
NIH CA 45831 "Inheritance and Markers of Colorectal Cancer and Polyps"
5/87-4/90. Funded for $200,285/$711,771. Co-investigator.
1992
Alpha I Biomedicals, Inc., "Thymosin Alpha 1 Treatment of Type B Virus
Chronic Hepatitis." 9/1/90 -10/1/94. Funded for $608,000. Co-Investigator.
1993
Amgen Inc., "A Phase III, Randomized, Double-Blind Controlled Trial of
Recombinant Methionyl Interferon Consensus in Patients with Chronic
Hepatitis C Virus (HCV) Infection," 2/1/93 - 4/30/95. Funded for $142,750.
Principal Investigator.
1994
Amgen Inc., "A Phase III, Open-Labeled, Randomized, Multicenter Trial to
Determine the Efficacy of Recombinent-Methionyl Interferon-Consensus in
Patients with Chronic Hepatitis C Virus after Prior Treatment with r-met IFNCon1, or Interferon alfa-2B recombinent," 9/1/94 - 9/30/99. Funded for
$107, 419. Principal Investigator.
1997 - 1999 Schering-Plough Integrated Therapeutics Group, Inc. Intron A + Ribavirin for
treatment of patients with Interferon/Refractory or Interferon/Relapsed
chronic hepatitis C. R96-419. $75,000. Co-Principal Investigator.
7
1998 - 1999 Schering-Plough Integrated Therapeutics Group, Inc. Health-Related
Quality of Life Questionnaire for Patients with Chronic Hepatitis C Who do
not qualify for combination study. R97-023. $75,000. Co-Principal
Investigator.
1998 - 2000 Schering-Plough Integrated Therapeutics Group, Inc. Intron A Induction
Protocol for Treatment of patients with chronic hepatitis C Who do not
qualify for combination study. R97-023. $75,000. Co-Principal Investigator.
1998 - 2000 Schering-Plough Integrated Therapeutics Group, Inc. Intron A + Ribavirin for
treatment of patients with chronic hepatitis C not previously treated with
Interferon. R97-024. $75,000. Co-Principal Investigator.
1998-2000 Amgen Inc. Consensus interferon (Infergen) treatment of chronic hepatitis
C patients who failed interferon/ribavirin therapy. Funded for $25,000. Coinvestigator.
1998-2003
Department of Veterans Affairs (VA Merit Review), Principal Investigators:
Adhip N. Majumdar, Ph.D, D.Sc. and Richard Jaszewski, M.D. CoInvestigator: Murray Ehrinpreis, M.D., Title: Colorectal Adenoma:
Chemoprevention by Folic Acid. $625,000 (Direct Cost). Score:20.7
2000-2007
Schering-Plough Integrated Therapeutics Group, Inc. Phase II study of
long term PEG Intron for patients who have failed to respond to
Rebetron/Interferon with advanced fibrosis and cirrhosis secondary to
hepatitis C. Funded for $30,000. Co-investigator.
PUBLICATIONS
Original Observations in Refereed Journals:
1.
Kreitzer S, Ehrinpreis M, Miguel E, and Petrasek J: Acute myoglobinuric renal
failure in polymyositis. NY State J Med 295-297, February 1978.
2.
Diazdeleon L, Ehrinpreis MN, Kershenobich D, and Rojkind M: Liver injury and
liver fibrogenesis, Metabolic Effects of Alcohol, (Developments in Nutrition and
Metabolism), vol l, (P Avogaro, CR Sirtori, E Tromoli, eds). Elsevier/North Holland
Biomedical Press, Amsterdam, 1979, pp 269-280.
3.
Ehrinpreis M, Giambrone M-A, and Rojkind M: Liver proline oxidase activity and
collagen synthesis in rats with cirrhosis induced by CCl4. Biochim Biophys Acta
629:184-193, 1980.
4.
Weinstock JV, Boros DL, Ehrinpreis MN, and Gee JB: The effect of SQ 14225, an
inhibitor of angiotensin I converting enzyme on the granulomatous response to
schistosoma mansoni in mice. J Clin Invest 67:93l-936, 1981.
5.
Cid AA, Pietruk T, Bidari CZ, and Ehrinpreis MN: Cecal fecaloma mimicking
colonic neoplasm. Dig Dis Sci 26:1134-1137, 1981.
8
6.
Beisel KW, Ehrinpreis MN, Bhathal PS, MacKay IR, and Rose NR: Genetics of
carbon tetrachloride-induced liver injury in mice. II. H-2 and non-H-2 control. Br J
of Exp Path 65:125-131,1984.
7.
Marcuard S, Ehrinpreis MN, and Fitter W: Gold-induced ulcerative proctitis:
Report and review of the literature. J Rheum 14 (1): 142-144, 1987.
8.
Luk GD, Moshier JA, and Ehrinpreis MN: Ornithine Decarboxylase as a Marker for
Colorectal Polyps and Cancer. Prog Clin Biol Res 279:227-39,1988.
9.
Ehrinpreis MN, Dhar R, and Narula A: Cimetidine-induced galactorrhea. Am Jour
Gastroenterol 84:563-565, 1989.
10.
Gupta TP and Ehrinpreis MN: Candida-associated diarrhea. Gastroenterology
98:780-785, 1990.
11.
Jaszewski R, Tolia V, Ehrinpreis M, Bodzin J, Peleman R, Korlipara R, and
Weinstock JV: Colonic Mucosal levels of angiotension I and II distinguish
Crohn's colitis from ulcerative colitis. Gastroenterology 98:1543-1548, 1990.
12.
Desai TK, Maliakkal JB, Kinzie JL, Ehrinpreis MN, Luk GD, and Cehja J: Taurine
depletion after intensive chemotherapy/radiation. Am J Clin Nutr 55:708-11, 1992.
13.
Barbish A and Ehrinpreis MN: Successful endoscopic injection sclerotherapy of a
bleeding duodenal varix and review of the literature. Am J Gastroenterol 88:90-92,
1993.
14.
Meyerson S, Desai TK, Polidori G, Raval MFT, and Ehrinpreis MN: A case of
intussusception and lymphoid hyperplasia in a patient with AIDS. Am J
Gastroenterol 88:303-306, 1993.
15.
Meyerson S, Holtz T, Ehrinpreis MN, and Dhar R: Small bowel obstruction during
pregnancy. Am J Gastroenterol 90:299-302, 1995.
16.
Alloju M and Ehrinpreis M: Shortage of intravenous multivitamin solution in the
United States (Brief case report, letter). N Eng J Med 337:54, 1997.
17.
Tong M, Reddy KR, Lee W, Pockros PJ, Hoefs JC, Ehrinpreis M, et al. Treatment
of chronic hepatitis C with consensus Interferon: A multicenter, randomized,
controlled trial. Hepatology 1997;26:747-754.
18.
Keeffe EB, Hollinger FB, Ehrinpreis M, et al. Therapy of hepatitis C: consensus
Interferon trials. Hepatology 1997;26,suppl:101S-107S.
19.
Heathcote EJ, Keeffe EB, Lee SS, Feinman SV, Tong MJ, Reddy KR, Albert DG,
Witt K, Blatt LM, Ehrinpreis MN, et al. Re-treatment of chronic hepatitis C with
consensus interferon. Hepatology 1998;27, 1136-1143.
9
20.
Nathani MG, Mutchnick MG, Tynes DJ, Ehrinpreis MN. An unusual case of
amoxicillin/clavulanic acid-related hepatotoxicity. Am J Gastroenterol
1998;93:1363-1365.
21.
Lee WM, Reddy KR, Tong MJ, Black M, van Leeuwen DJ, Hollinger, FB, Mullen
KD, Pimstone N, Albert D, Gardner S, Ehrinpreis MN, et al. Early Hepatitis C virusRNA responses predict interferon treatment outcomes in chronic hepatitis C.
Hepatology 1998;28:1411-1415.
22.
Zagnoon A, Ehrinpreis MN: Impacted Pigment Gallstone. Gastrointest.
Endoscopy 1999; 49:626.
23.
Bonkovsky HL, Woolley JM, Ehrinpreis MN, et al. Reduction of health-related
quality of life in chronic hepatitis C and improvement with interferon therapy.
Hepatology 1999; 29:264-270.
24.
Everson GT, Jensen DM, Craig JR, VanLeeuwen DJ, Bain VG, Ehrinpreis MN, et
al: Efficacy of interferon treatment for patients with chronic hepatitis C: Comparison
of response in cirrhotics, fibrotics or nonfibrotics. Hepatology 1999; 30:271-276.
25.
Mutchnick MG, Lindsay KL, Schiff ER, Cummings GD, Appelman HD, Peleman
RR, Silva M, Roach KC, Simmons F, Milstein S, Gordon SC, Ehrinpreis MN, :
Thymosin - ά, treatment of chronic hepatitis B: results of a phase III multicenter,
randomized, double-blind and placebo - controlled study. J. Viral Hep. 1999;
6:397- 403.
26.
Xiao Z-Q, Yu Y, Khan A, Jaszewski R, Ehrinpreis MN, Majumdar APM: Induction of
G1 checkpoint in the gastric mucosa of aged rats. Am. J. Physiol.
Gastrointest./Liver physiol. 1999; 277 (Gastroentest Liver Physiol 40; G929-G934.
27.
Reddy RK, Hoofnagle JH, Tong JM, Lee WM, Pockros, E, Heathcote J, Albert D,
Joh T, Ehrinpreis MN, et al. Racial differences in responses to therapy with
interferon in chronic hepatitis C. Hepatology 1999; 30: 787-793.
28.
Keeffe EB, Dusheiko GM, Tong MJ, Hollinger FB, Heathcote EJ, McHutchison J,
Albert D, Ehrinpreis MN, et al. Genotype does not affect pattern of HCV RNA
decrease among responders during interferon treatment of chronic hepatitis C.
Cytokines Cell Mol Ther 1999; 5: 211-6.
29.
Keefe EB, Dusheiko GM, James SP, Mullen KD, Everson GT, Pimstone NR,
Donovan J, Albert D, Ehrinpreis MN, et al. Utility of hepatitis C virus serotypes in
predicting response to treatment of chronic hepatitis C. Cytokines Cell Mol Ther
1999; 5: 207-10.
30.
McHutchison JG, Blatt LM, deMedina M, Craig JR, Conrad A, Schiff ER,
Tong MJ, Ehrinpreis MN, et al. Measurement of serum hyaluronic acid in
patients with chronic hepatitis C and its relationship to liver histology.
J Gastroenterol Hepatol 2000; 15: 945-51.
10
31.
.
32.
Siddiqui F, Mutchnick M, Kinzie J, Peleman R, Naylor P, Ehrinpreis M.
Prevalence of hepatitis A virus and hepatitis B virus immunity in patients with
PCR-confirmed hepatitis C: implications for vaccination strategy. Am J
Gastroenterol 2001; 96: 858-63.
Kinzie JL, Naylor PH, Nathani MG, Peleman RR, Ehrinpreis MN, Lybik M, Turner
JR, Janisse JJ, Massanari M, Mutchnick MG. African Americans with genotype 1
treated with interferon for chronic hepatitis C have a lower end of treatment
response than Caucasians. J Viral Hepat 2001; 8: 264-9.
33.
Ullah N, Yeh R, Ehrinpreis M. Fatal hyperphosphatemia from a phospho-soda
bowel preparation: a case report. J Clin Gastroenterol 2002; 34: 457-8.
34.
Nagothu K, Jaszewski R, Moragoda L, Rishi AK, Finkenauer R, Tobi M, Naumoff
JA, Dhar R, Ehrinpreis M, Kucuk O, Majumdar APN. Folic acid mediated
attenuation of loss of heterozygosity of DCC tumor suppressor gene in the
colonic mucosa of patients with colorectal adenomas. Cancer Detection and
Prevention 2003; 27: 297-304.
35.
Ehrinpreis M. Debate-Should the National GI fellowship matching program
be restored? Con: the gastroenterology fellowship match: R.I.P. Am J
Gastroenterol 2004; 99:7-9.
36.
Perez NE, Phillips CR, Webber JD, Guzman CB, Saksouk FA, Ehrinpreis
MN. Jejunal obstruction caused by a calcified enterolith. Pract Gastroenterol 2006; 30:49-53.
37.
Perez NE, Siddiqui FA, Mutchnick MG, Dhar R, Tobi M, Ullah N, Saksouk FA,
Wheeler DE, Ehrinpreis MN. Ultrasound diagnosis of fatty liver in patients
with chronic liver disease; a retrospective observational study. J Clin
Gastroenterol 2007;41:624-9.
38.
Pawa S, Ehrinpreis M, Mutchnick M, Janisse J, Dhar R, Siddiqui FA.
Percutaneous liver biopsy is safe in chronic hepatitis C patients with end
stage renal disease. Clin Gastroenterol Hepatol 2007 (in press).
39.
Pawa S, Khalifa AJ, Ehrinpreis MN, Schiffer CA, Siddiqui FA. Zinc toxicity
from massive and prolonged coin ingestion in an adult. Am J Med Sci 2007
(in press).
11
Original Observations in Non-Refereed Journals:
1.
Luk GD, Moshier JA, and Ehrinpreis MN: Ornithine decarboxylase: A new
marker for colorectal polyps and cancer? Dept. Med. Bulletin, Wayne State
University. 2:4-10,1988.
Review Articles:
1.
Ehrinpreis MN: Recent Advances in Gastroenterology, IAD Buchier (editor),
Churchill Livingstone, New York, 1980. N Eng J Med 304:367, 1981.
2.
Ehrinpreis MN: Nutrition and Diet Therapy in Gastrointestinal Disease. MH Floch
(editor), Plenum Press, New York, 1981. N Eng J Med 306:943, 1982.
3.
Ehrinpreis MN: Clinical Nutrition, Taylor KB and Anthony LE, McGraw-Hill, New
York, 1983 and Obesity. MRC Greenwood (editor), Churchill Livingstone, New
York, 1983, N Eng J Med 309:1332, 1983.
4.
Ehrinpreis MN, Kinzie JL, Jaszewski R, and Peleman RR: Management of the
malignant polyp. Gastroenterology Clin. N. Amer., 17:837-850, 1988.
5.
Peleman RR, Kinzie JL, Desai TK, and Ehrinpreis MN: Colonoscopic
polypectomy. Gastroenterology Clin. N. Amer. 17:851-858, 1988.
6.
Silverman AL, Desai TK, Dhar R, Ehrinpreis MN, Kinzie JL, and Luk GD: Clinical
features, evaluation, and detection of colorectal cancer. Gastroenterology Clin. N.
Amer. 17:713-725, 1988.
7.
Ehrinpreis MN: Anorectal Disease in AIDS. TG Allen-Mersh and L Gottesman
(editors) Edward Arnold, London, 1991, N Eng J Med 328:451-2, 1993.
8.
Mutchnick MG, Ehrinpreis MN, Kinzie JL, and Peleman RR: Prospectives on the
treatment of chronic hepatitis B and chronic hepatitis C with thymic peptides and
antiviral agents. Antiviral Research 24:245-257, 1994.
9.
Jaszewski R, Ehrinpreis MN, Majumdar APN: Aging and cancer of the
stomach and colon. Frontiers in Bioscience 4:322-328, 1999.
Books and Chapters:
1.
Ehrinpreis MN: Nutrition in Hepatic Failure. Nutrition and Metabolism in the
Surgical Patient. JR Kirkpatrick and MS Dahn (Editors), Futura, Mt. Kisco, New
York, pp 357-383, 1983.
2.
Luk GD, Moshier JA, Ehrinpreis MN: Ornithine Decarboxylase as a Marker for
Colorectal Polyps and Cancer. Basic and Clinical Perspectives of Colorectal Polyps
and Cancer. Steele G Jr, Burt RW, Winawer SJ, Karr JP (Eds), Progress in Clinical
and Biological Research 1988;279:227-239.
3.
Ehrinpreis MN, Alousi MA: Atrophic gastritis. Gastritis, RA Kozol (Editor), CRC
Press, Boca Raton, pp 159-182, 1993.
12
4.
Ehrinpreis MN: Toxic Megacolon, Diarrhea, Lower Gastrointestinal
Hemorrhage (3 chapters). The Saunders Manual of Critical Care, JA Kruse
(Editor), W.B.Saunders Company, Orlando, Florida, pp 466-476, 2003.
Educational Material
1.
Monograph: "Jaundice: A problem-oriented approach" for Year II Wayne State
University Gastrointestinal Pathophysiology Course syllabus.
PUBLISHED ABSTRACTS:
1.
Ehrinpreis M, M Rojkind, and M-A Giambrone: Dynamics of liver collagen
synthesis in CC14-treated rats. Gastroenterology 73(5):A33, 1977.
2.
Rojkind M, M-A Giambrone, and M Ehrinpreis: Proline oxidase activity and the
availability of proline for collagen biosynthesis in livers in CC14- treated rats.
Gastroenterology 73(5):A131, 1977.
3.
Ehrinpreis M and K Gasser: Relationship between hepatic and plasma free proline
concentrations in CC14-treated rats. Gastroenterology 77(5):A10, 1979.
4.
Weinstock JV, DL Boros, MN Ehrinpreis, and JB Gee: Effect of angiotensin I
converting enzyme (ACE) inhibitor on the granulomatous response to schistosoma
mansoni eggs in mice. Gastroenterology 78(5):1289, 1980.
5.
Ehrinpreis M and K Gasser: Free proline generation and the increased free proline
pool in fibrotic liver of CC14-treated rats. Gastroenterology 79(5):1014, 1980.
6.
Ehrinpreis M, K Gasser, and E Urdanivia: Hepatic collagen and free proline
concentrations in rats with experimental diabetes mellitus. Gastroenterology
80(5):1331, 1981.
7.
Beisel KW, PS Bhathal, MN Ehrinpreis, IR MacKay, and NR Rose: Genetic control
of murine susceptibility to carbon tetrachloride-induced liver damage. Fed Proc
40(3, pt. 1):765, 1981.
8.
Ehrinpreis M, L Lai, and K Beisel: Carbon tetrachloride (CCl4)-induced hepatic
fibrosis in inbred mouse strains. Hepatology 2:700, 1982.
9.
Jaszewski R, M Ehrinpreis, and L Lai: Cimetidine and centrizonal necrosis confer
resistance to acetaminophen hepatotoxicity in mice. Hepatology 2:700, 1982.
l0.
Flore MR, V Wojnar, and MN Ehrinpreis: Impact of skin testing during TPN in a
cancer patient population. JPEN 9:l24, l985.
11.
Ahmad I, M Ehrinpreis, A Narula, A Mehdiratta, J Kinzie, and E Luby: Prolonged
intestinal transit time in eating disorder patients. Clinical Research 35(2), 1987.
13
12.
Gupta T and MN Ehrinpreis: Candida-associated diarrhea in hospitalized
patients. Gastroenterology 94(5): 162, 1988.
13.
Madhok D, R Peleman, MN Ehrinpreis, C Sugawa, GD Luk, and AL Silverman:
The presence of ascites is associated with infections and fever after sclerotherapy.
Gastroenterology 94(l5): 277, 1988.
14.
DeVore MS and Ehrinpreis MN: Comparison of dosages of diazepam versus
midazolam in GI endoscopy. Gastrointestinal Endoscopy 34(2)" 171, 1988.
15.
Korlipara AP, Ehrinpreis MN, Luk GD, and Peleman RR: Blind cytology brushing
as a method of diagnosis of esophageal candidiasis. Gastrointestinal Endoscopy
34(2): 205, 1988.
16.
Jaszewski R, Weinstock JV, Tolia V, Ehrinpreis M, Bodzin J, Peleman, R, and
Korlipara R: Colonic mucosal levels of angiotensin I (AI) and II (AII) distinguish
Crohn's colitis from ulcerative colitis. Gastroenterology 96(5): A238, 1989.
17.
Gupta T, Maliakkal BJ, Peleman R, Ehrinpreis M, Weaver D, and Luk GD:
Complications of surgical (SG) and percutaneous endoscopic gastrostomy (PEG).
Gastroenterology 96(5): A190, 1989.
18.
Neelam S, Maliakkal BJ, Ehrinpreis, Luby E, Martin S, Luk GD, and Kinzie J: Total
parenteral nutrition (TPN) in primary anorexia nervosa (AN). Gastroenterology
96(5): A362, 1989.
19.
Mehta R, Martin S, Kudla V, Ehrinpreis M, Kinzie J, and Luk GD: Comparison of
the incidence of catheter related sepsis (CPS) in hospital (ITPN) and home-treated
patients (HTPN) with total parenteral nutrition. Gastroenterology 96(5): A339,
1989.
20.
Maliakkal BJ, Kinzie J, Neelam S, Luby E, Ehrinpreis M, Martin S, and Luk GD:
Admission laboratory values in the assessment of nutritional status in anorexia
nervosa. Gastroenterology 96(5): A376, 1989.
21.
Lans J, Ehrinpreis M, Poplin E, Baker, Luk GD, and Peleman R: Gastrointestinal
complications of hepatic artery infusion (HAI) pumps. Gastroenterology 96(5):
A286, 1989.
22.
Desai T, Hinch L, Shah S, Ehrinpreis M, and Kinzie J: Elemental diet/ intralipid
restricted regimen reduces risk of bacteremia in bone marrow transplantation.
JPEN 14:21S, 1990.
23.
Desai TK, Mehta R, Lan G, Kinzie JL, Luk GD, and Ehrinpreis MN: Intralipid
infusions and septicemia in bone marrow transplant recipients. Gastroenterology
98(5):A409, 1990.
Desai TK, Meyerson S, Hinch L, Kinzie J, Ehrinpreis MN, Peleman R, Lum L, et al.:
Strict elemental diet/intralipid (IL) restricted parenteral nutrition (PN) may reduce
gram negative bacteremia in allogeneic bone marrow transplantation.
Gastroenterology 100(5):A519, 1991.
24.
14
25.
Maliakkal BJ, Katta S, Cejka J, Ehrinpreis MN, Kinzie JL, and Desai TK: Severe
acute taurine deficiency after cancer chemotherapy. Gastroenterology 100(5):
A534, 1991.
26.
Reddy J, Bakst C, Cronin S, Kinzie J, Ehrinpreis MN, Desai TK, et al.: Lipid
restriction may reduce severity of parenteral nutrition (PN) related liver disease in
bone marrow transplantation (BMT). Gastroenterology 100(5):A544, 1991.
27.
Barbish AW and Ehrinpreis MN: Successful sclerotherapy of bleeding duodenal
varices. Am J Gastroenterol 86:1366, 1991.
28.
Tobi M, Kaila V, Goo R, Kinzie J, Ehrinpreis M, Maliakkal B, Yang S, Chintalapani
S, Cats A, and Luk G: An adenoma-associated antigen as a proneoplastic marker
in familial polyposis coli versus sporadic colonic neoplasia. Gastroenterology
102(4): A403, 1992.
29.
Polidori G, Holtz T, Kinzie J, Kellogg C, Ehrinpreis M, and Peleman R: A cluster of
rota-virus associated diarrhea identified in bone-marrow- transplant recipients.
Gastroenterology 102(4):A680, 1992.
30.
Meyerson S, Peleman R, and Ehrinpreis M: Prevalance of helicobacter pylori (HP)
in HIV infected patients compared to age-matched controls using urease testing.
Am J Gastroenterol 87(9):1272, 1992.
31.
Desai TK, Reddy J, Kinzie JL, Ehrinpreis MN. Taurine supplementation and
cholestasis during bone marrow transplantation. Gastroenterology 104:A616,
1993.
32.
Meyerson S, Holtz T, Ehrinpreis MN, and Dhar R. Small bowel obstruction during
pregnancy. Am J Gastroenterol 88(9):1593, 1993.
33.
Shah G, Augustine S, Cummings G, Ehrinpreis M. Pre-eclampsia, liver function
abnormalities and cocaine use during pregnancy. Gastroenterology 106:A980,
1994.
34.
Reddy R, Blatt LM, Conrad A, Tong MJ, Lubina J, Smith C, Ehrinpreis MN, Bala K,
Willems BE, White H, Black M, Donovan J, Bailey RJ, and the Consensus
Interferon Study Group. Genotype distribution in 815 chronic HCV infected
patients in North America. Gastroenterology 110:A1303, 1996.
35.
Hollinger FB, Blatt LM, Tong MJ, Conrad A, Balart L, Pockros P, Bonkovsky HL,
Ehrinpreis MN, Lubina J, and the Consensus Interferon Study Group. Differential
response to treatment with consensus interferon and IFN-α 2b in chronic HCV
patients infected with genotype 1b. Gastroenterology 110:A1213, 1996.
36.
Craig JR, Bain VG, Black M, Cruickshank S, Ehrinpreis M, Foust R, Hofling D, Lee
W, Sarosi I, Smith CI, Van Leeuwen DJ, and the Consensus Interferon Study
Group. Liver histology improvement is associated with ALT and HCV RNA
response following treatment with consensus interferon (CIFN). Gastroenterology
110:A1175, 1996.
15
37.
Naylor PH, Nathani M, Peleman R, Ehrinpreis MN, Mutchnick MG. Comparison
of two HBV-DNA hybridization assays of sera from patients completing a clinical
trial of thymosin α1 (Tα1) in chronic hepatitis B (CHB). Gastroenterology
110:A1276, 1996.
38.
Craig JR, Bain VG, Ehrinpreis M, Foust R, Lee W, Smith CI, van Leeuwen DJ, and
the Consensus Interferon Study Group. Liver histology improves in both cirrhotic
and non-cirrhotic patients with chronic HCV infection following consensus
interferon (CIFN) therapy. Gastroenterology 112:A1248, 1997.
39.
Nathani M, Ehrinpreis M, Naylor P, Lybik M, Peleman R, Kinzie J, Mutchnick
M. The demographic analysis of chronic hepatitis C patients within a
metropolitan community practice. Gastroenterology 114:L0460, 1998.
40.
Siddiqui F, Nathani M, Kumar A, Mutchnick M, Peleman R, Kinzie J,
Ehrinpreis M. Prevalence of hepatitis A and hepatitis B immunity in
patients with PCR- confirmed hepatitis C. Gastroenterology 114:L0597
1998.
41.
Shahzad S, Bentley G, Nathani MG, Naylor PH, Ehrinpreis MN, Peleman RR,
Kinzie JL, Mutchnick MG. Viral load, age, race, gender and serum
transaminase levels predict histological grade and stage in hepatitis C virus
(HCV) infection. Hepatology 28; 201A, 1998.
42.
Ehrinpreis MN, Nathani MG, Naylor PH, Peleman RR, Kinzie JL, Lybik M,
Mutchnick MG. Race, hepatitis C genotype and ALT>AST predict the
probability of response to interferon in an urban clinic population of patients
with chronic hepatitis C. Hepatology 28; 204A, 1998.
43.
Everson GT, Jensen DM, Craig JR, vanLeewen DJ, Bain VG, Ehrinpreis MN,
Albert D, Joh T, Witt K, et al. Efficacy of interferon treatment for patients with
chronic hepatitis C: comparison of response in cirrhotics, bridging fibrotocs,
or nonfibrotics. Hepatology 28; 209A, 1998.
44.
Peleman RR, Naylor PH, Ehrinpreis MN, Nathani MG, Kinzie JL, Lybik M,
Siddiqui F, Mutchnick MG. Serum HCV RNA levels as determinants for dose
escalation of interferon: results from studies in an urban clinic population.
Hepatology 28; 370A, 1998.
45.
Nathani MG, Naylor PH, Ehrinpreis MN, Kinzie JL, Lybik M, Peleman RR,
Mutchnick MG. Three negative PCR for HCV RNA at intervals of one month
are not adequate to predict a sustained response to interferon. Hepatology
28; 702A, 1998.
46.
Siddiqui F, Naylor PH, Ehrinpreis MN, Peleman RR, Kinzie JL, Mutchnick MG:
Induction interferon treatment of African-Americans with hepatitis C results
in an enhanced response comparable to Caucasians given standard
interferon therapy. Gastroenterology 116: A820, 1999.
16
47.
Ullah N, Siddiqui FA, Naylor PH, Kinzie JL, Ehrinpreis MN, Peleman RR,
Mutchnick MG. Presence of hepatitis B virus core antibodies (Anti-HBC) in
chronic hepatitis C patients is predictive of a decreased end of treatment
response (ETR) to interferon. Hepatology 30:195A, 1999.
48.
Kinzie JL, Naylor PH, Ehrinpreis MN, Khan N, Siddiqui FA, Peleman
RR, Mutchnick, MG. Reluctance of urban clinic patients to undergo
treatment with interferon-alpha. Hepatology 30: 266A, 1999.
49.
Naylor PH, Brown KA, Gordon SC, Moonka D., Silverman AL, Kinzie
JL, Ehrinpreis MN, Peleman RR, Mutchnick MG. Response to retreatment with
interferon/ribavirin in Caucasian and African American relapsers and
nonresponders. Hepatology 30: 373A, 1999.
50.
Naylor PH, Podzorski R, Dhar R, Ehrinpreis MN, Kinzie JL, Siddiqui F,
Mutchnick MG. Two laboratory methods for measuring serum HCV RNA in patients
with hepatitis C are equal with respect to determining and predicting end of
treatment response to interferon therapy. Antiviral Therapy 4(supplement 4) A87,
1999.
51.
Naylor PH, Kinzie JL, Ehrinpreis MN, Siddiqui F, Dhar R, Turner JR, Mutchnick MG.
Retreatment of interferon failures with combination therapy: log drop after 12 weeks
of monotherapy predicts ETR to combination therapy. Antiviral Therapy 5: C191,
2000.
52.
Khalifa-Alsaleh A, Naylor PH, Kinzie JL, Ehrinpreis MN, Siddiqui F, Dhar R, Turner
JR, and Mutchnick MG.: End of treatment response (ETR) to Intron A monotherapy
in chronic hepatitis C is similar in patients with normal and elevated ALT. Antiviral
Therapy 2000; 5: C190.
53.
Weidler N, Naylor PH Patel CM, Chilukuri S, Mendu S, Janisse JJ, Dhar R,
Ehrinpreis MN, Kinzie JL, Siddiqui F, Turner JR, Mutchnick MG. Demographical
and biochemical influences on quality of life scores in urban patients with Hepatitis
C. Gastroenterology 2000; 118(Supp 2): A995
54.
Kulkarni PM, Kinzie JL, Ehrinpreis MN. Argon plasma coagulator treatment in the
management of hematochezia secondary to chronic radiation proctopathy. Am J
Gastroenterol 2000; 95:2539.
55.
Ullah N, Yeh R, Ehrinpreis MN. Fatal hyperphosphatemia after oral phospho-soda
preparation for colonoscopy: a case report and review of the literature. Am J
Gastroenterol 2000; 95: 2613.
56.
Yeh R, Ullah N, Ehrinpreis MN. Role of lamivudine in the treatment of acute
hepatitis B infection associated with polyarteritis nodosa. Am J Gastroenterol 2000;
95: 2615.
17
57.
Naylor PH, Meija L, Kinzie JL, Ehrinpreis MN, Dhar R, Siddiqui F, Turner JR,
Mutchnick MG. Tumor necrosis factor-a and chronic hepatitis C: lower serum levels
in African Americans as compared to Caucasians. Hepatology 2000; 32(pt. 2):
263A.
58.
Alawad G, Naylor PH, Hemacha A, Jamma K, Weidler N, Kinzie JL,
Ehrinpreis MN, Dhar R, Mutchnick MG.: Differences in side effect profiles and
response to combination ribavirin and interferon a2b (IFN) therapy between
Caucasians and African Americans with chronic hepatitis C. Hepatology 2000;
32(pt. 2): 368A.
59.
Siddiqui FS, Naylor PH, Ehrinpreis MN, Dhar R, Turner J, Murthy R, Kulkarni P,
Boag J, Mutchnick MG: Biochemical, histological and clinical comparisons between
African-American and Caucasian patients with chronic hepatitis C in an urban clinic
population. Gastroenterology 2001; 120(Suppl 1): A365.
60.
Khalifa A, Siddiqui F, Ehrinpreis M. A case of zinc toxicity due to massive coin
ingestion. Am J Gastroenterol 2001;96(Suppl):S213.
61.
Ullah N,Lucas D, Yeh R, Akhras J, Ehrinpreis M, Kulkarni P. Overt-obscure GI
bleeding from an unusual small bowel lesion in an HIV patient previously treated
for Kaposi’s sarcoma. Am J Gastroenterol 2001;96(Suppl):S353.
62.
Kulkarni PM, Mutchnick MG, Ehrinpreis MN. Sero-prevalence of hepatitis B and C
in a large university-based sickle-cell practice. Hepatology 2001;34(4pt.2):564A.
63.
Shahin G, Naylor PH, Mutchnick MG, Siddiqui FA, Turner JR, Dhar R, Murthy R,
Ehrinpreis MN. Influence of hepatitis C infection on gallstone prevalence in urban
patients. Hepatology 2001;34(4pt.2):565A.
64.
Kulkarni PM, Mutchnick MG, Migdal SD, Ehrinpreis MN. Hepatitis B and C in urban
hemodialysis centers: a Detroit experience. Hepatology 2001;34(4pt.2):565A.
65.
Siddiqui FA, Ehrinpreis MN, Naylor PH, Dhar R, Murthy R, Boag J, Mutchnick MG.
Response to combination treatment in African-American patients with chronic
hepatitis C is significantly lower compared to Caucasians. Hepatology
2001;34(4pt.2):581A.
66.
Siddiqui FA, Naylor P, Ehrinpreis M, Dhar R, Murthy R, Mutchnick M. AfricanAmericans with chronic hepatitis C respond poorly to interferon/ribavirin
combination treatment even when induction regimens are used. Gastroenterology
2002;123(1suppl.1):77A (T1402).
67.
Al-Subee O, Ehrinpreis M, Tyburski J. Pneumatosis coli associated with
cryptosporidiosis of the GI tract in AIDS patients. Am J Gastroenterol
2002;97(Suppl):S169.
68.
Siddiqui F, Ehrinpreis M, Singh A, Dhar R, Murthy R, Mutchnick M. Prevalence of
chronic hepatitis C infection in patients with hepatocellular carcinoma in an inner
city population. Hepatology 2002;36(4pt.2):703A.
18
69.
Zalewska I, Siddiqui F, Ehrinpreis M, Dhar R, Murthy R, Ranieri L, Janisse J,
Mutchnick M. African Americans failing treatment with interferon monotherapy for
chronic hepatitis C are less likely to achieve sustained response to subsequent
treatments compared to Caucasians. Gastroenterology 2003;124(4suppl.1):A781(T1278).
70.
Pawa S, Ehrinpreis MN, Mutchnick MG, Dhar R, Siddiqui F. Percutaneous
liver biopsy in chronic hepatitis C patients with end stage liver disease.
Gastroenterology 2004;126(4suppl.2):A719(M1220).
71.
Duttala S, Al-Subee O, Ehrinpreis M. Retrospective analysis of patients
diagnosed with colorectal cancer above age of 75 by colonoscopy.
Gastrointest Endosc 2004;59:AB280(W1656).
72.
Pawa S, Mutchnick M, Ehrinpreis M, Dhar R, Greer J, Siddiqui FA. Patients
with chronic hepatitis C and chronic renal insuffieiency or end stage renal
disease respond poorly to interferon monotherapy. Hepatology
2004;36(4suppl.1):332-333A.
73.
Perez N, Ullah N, Tobi M, Wheeler D, Saksouk F, Ehrinpreis M. Fat or fiction:
ultrasound diagnosis of fatty liver in patients with chronic liver disease. Am
J Gastroenterol 2005;100(9Suppl):S108.
74.
Perez N, Phillips C, Webber J, Ehrinpreis M. Jejunal obstruction caused by
an enterolith. Am J Gastroenterol 2005;100(9Suppl):S204.
75.
Khan A, Mutchnick M, Ehrinpreis M, Dhar R, Siddiqui F. African-Americans
with genotype-1 with chronic hepatitis C respond poorly to pegylatedinterferon and ribavirin combination treatment as compared to Caucasians.
Am J Gastroenterol 2005;100(9Suppl):S126.
76.
Hammad H, Diez A, Perez N. Wiese W, Ehrinpreis, M. Hepatitis B flare after
cessation of HAART. Am J Gastroenterol 2006;101(9 Suppl):S282.
77.
Pawa S, Greene M, Ehrinpreis, M. Ischemic colitis associated with epsilonaminocaproic acid therapy. Am J Gastroenterol 2006;101(9 Suppl):S285.
78.
Maryala S, Perez N, Chandravanka C, Ehrinpreis M. Esophageal
actinomycosis. Am J Gastroenterol 2006;101(9 Suppl):S286.
79.
Reyes P, Pawa S, Ehrinpreis M. Intestinal Ganglioneuromatosis Polyposis:
A rare cause of abdominal pain. Am J Gastroenterol 2006; 101(9
Suppl):S378.
80.
Hammad H, Perez N, Dahche T, Ehrinpreis M. GVHD of the GI tract after BMT:
are both upper and lower endoscopies necessary to make the diagnosis?
Gastroenterology 2007;132(4Suppl2):A193(S1197).
19
81.
Hammad H, Razumilava N, Perez N, Ehrinpreis M. Gastrointestinal
bleeding in biopsy-proven graft-versus-host disease of the GI tract: risk
factors and effect on mortality. Am J Gastroenterol 2007;102(9Suppl):S453.
82.
Seren S, Bayraktar U, Ehrinpreis M. Characteristics of patients with reflux
esophagitis, non-erosive reflux disease and functional heartburn. Am J
Gastroenterol 2007;102(9Suppl):S130.
83.
Seren S, Bayraktar U, Ehrinpreis M. Esophageal pH monitoring with Bravo™
capsule in patients with suspected gastroesophageal reflux disease. Am J
Gastroenterol 2007;102(9Suppl):S130.
PRESENTATIONS:
Invited Internationally:
1.
Invited Speaker: Marmara University Hospital, Istanbul, Turkey, April 29, 1994 May11, 1994, Lectures and Endoscopic Procedures.
2.
Ehrinpreis MN: Inflammatory bowel disease. Plenary presentation and
symposium at 24th International Congress of Internal Medicine, Lima, Peru.
November 4-5, 1998.
Invited Nationally:
1.
Flore MR, V Wojnar, and MN Ehrinpreis: Impact of skin testing done during TPN in
a cancer patient population. Presented at ASPEN 9th Clinical Conference, Miami
Beach, January 22, 1985.
2.
Facca B, M Ehrinpreis, and L Franchina: Serum transferrin and nitrogen balance.
Presented at Nutrition Practice Poster Session, ASPEN 12th Clinical Conference,
Las Vegas, January 19, 1988.
3.
Gupta T and MN Ehrinpreis: Candida-associated diarrhea in hospitalized patients.
Presented at the AGA National Meeting, New Orleans, May 18, 1988.
4.
"Cytotec Study Investigators Seminar, Searle Corporation." Scottsdale, Arizona,
March 12, 1988.
5.
Jaszewski R, Weinstock JV, Tolia V, Ehrinpreis M, Bodzin J, Peleman R, and
Korlipara P: Colonic mucosal levels of angiotensin I and II distinguish Crohn's
colitis from ulcerative colitis. Presented at the AGA national meeting, Washington
DC, May 1989.
6.
Desai T, Hinch L, Shah S, Ehrinpreis M, and Kinzie J: Elemental diet/ intralipid
restricted regimen reduces risk of bacteremia in bone marrow transplantation.
Presented at ASPEN 14th Clinical Conference, San Antonio, Jan 29, 1990.
7.
Castillo M and Ehrinpreis MN: Diarrhea in hospitalized patients: The roles of stool
cultures, antibiotics, candida. Presented at the Midwest Gut Club, Detroit, MI,
March 3, 1990.
20
8.
Spitzer AR and Ehrinpreis M: Electrophysiologic distinction of Serotonin responsive and unresponsive myoclonus. Presented at the First International
Congress of Movement Disorders, Washington, D.C., April 1990.
9.
Desai TK, Mehta R, Lan G, Kinzie JL, Luk GD, and Ehrinpreis MN: Intralipid
infusions and septicemia in bone marrow transplant recipients. Presented at the
AGA national meeting, San Antonio, May 16, 1990.
10.
Ehrinpreis MN: "Update on Nutrition in Hospitalized Patients." Presented at
Medical Grand Rounds, Texas Tech. University, El Paso, Texas, April 6, 1990.
11.
Desai TK, Meyerson S, Hinch R, Kinzie JL, Peleman R, Lum L, Ehrinpreis MN, and
the Bone Marrow transplant team: Strict elemental diet/intralipid restricted
parenteral nutrition may reduce gram negative bacteremia in allogenic bone
marrow transplantation. Presented at AGA national meeting, New Orleans, May
1991.
12.
Tobi M, Kaila V, Goo R, Kinzie J, Ehrinpreis M, Maliakkal B, Yang S, Chintalapani
S, Cats A, and Luk G: An adenoma-associated antigen as a proneoplastic marker
in familial polyposis coli versus sporadic neoplasia. Presented at AGA National
Meeting, San Francisco, May 13, 1992.
13.
Meyerson S, Peleman R, and Ehrinpreis M: Prevalence of Helicobacter pylori (HP)
in HIV infected patients compared to age-matched controls using urease testing.
Presented at ACG National Meeting, Miami Beach, October 26, 1992.
14.
Desai TK, Reddy J, Kinzie JL, and Ehrinpreis MN: Taurine supplementation and
cholestasis during bone marrow transplantation. Presented at the AGA National
Meeting, Boston, May 18, 1993.
15.
Meyerson S, Holtz T, Ehrinpreis MN, and Dhar R: Small bowel obstruction during
pregnancy. Presented at the ACG National Meeting, New York, October 4, 1993.
16.
Reddy R, Blatt LM, Conrad A, Tong MJ, Lubina J, Smith C, Ehrinpreis MN, Bala K,
Willems BE, White H, Black M, Donovan J, Bailey RJ, and the Consensus
Interferon Study Group. Genotype distribution in 815 chronic HCV infected
patients in North America. Presented at AGA National Meeting, San Francisco,
May, 1996.
17.
Hollinger FB, Blatt LM, Tong MJ, Conrad A, Balart L, Pockros P, Bonkovsky HL,
Ehrinpreis MN, Lubina J, and the Consensus Interferon Study Group. Differential
response to treatment with consensus interferon and IFN-" 2b in chronic HCV
patients infected with genotype 1b. Presented at AGA National Meeting, San
Francisco, May, 1996.
18.
Lybik M, Naylor PH, Nathani MG, Peleman RR, Ehrinpreis MN, Kinzie JL,
Mutchnick MG. The demographics and analysis of the routes of acquisition of
hepatitis C in a community practice. Presented at the 2nd International Conference
on Therapies for Viral Hepatitis, Big Island, Hawaii, December 18, 1997.
21
19.
Nathani MG, Naylor PH, Lybik M, Peleman RR, Ehrinpreis MN, Kinzie JL,
Mutchnick MG. Distribution of HCV RNA and genotype in a community practice
setting. Presented at the 2nd International Conference on Therapies for Viral
Hepatitis, Big Island, Hawaii, December 18, 1997.
20.
Siddiqui F, Nathani M, Kumar A, Mutchnick M, Peleman R, Kinzie J, Ehrinpreis M.
Prevalence of hepatitis A and hepatitis B immunity in patients with PCR-confirmed
hepatitis C. Presented at the Midwest Gut Club Meeting, Cleveland, Ohio, March
1998.
21.
Siddiqui F, Nathani M, Kumar A, Mutchnick M, Peleman R, Kinzie J, Ehrinpreis M.
Prevalence of Hepatitis A and Hepatitis B Immunity In Patients With PCRConfirmed Hepatitis C. Presented at the Digestive Disease Week, New Orleans,
LA. May 18, 1998.
22.
Shahzad S, Bentley G, Nathani MG, Naylor PH, Ehrinpreis MN, Peleman RR,
Kinzie JL, Mutchnick MG. Viral load, age, race, gender and serum transaminase
levels predict histological grade and stage in hepatitis C C virus (HCV) infection.
Presented at the International Association for the Study of the Liver, Bienniel
Scientific Meeting, Chicago, IL. November 4, 1998.
23.
Ehrinpreis MN, Nathani MG, Naylor PH, Peleman RR, Kinzie JL, Lybik M,
Mutchnick MG. Race, hepatitis C genotype and ALT>AST predict the probability of
response to interferon in an urban clinic population of patients with chronic hepatitis
C. Presented at the International Association for the Study of the Liver, Bienniel
Scientific Meeting, Chicago, IL. November 4, 1998.
24.
Everson GT, Jensen DM, Craig JR, vanLeewen DJ, Bain VG, Ehrinpreis MN,
Albert D, Joh T, Witt K, et al. Efficacy of interferon treatment for patients with
chronic hepatitis C: Comparison of response in cirrhotics, bridging fibrotocs, or
nonfibrotics. Presented at the International Association for the Study of the Liver,
Bienniel Scientific Meeting, Chicago, IL. November 4, 1998.
25.
Peleman RR, Naylor PH, Ehrinpreis MN, Nathani MG, Kinzie JL, Lybik M, Siddiqui
F, Mutchnick MG. Serum HCV RNA levels as determinants for dose escalation of
interferon: results from studies in an urban clinic population. Presented at the
American Association for the Study of Liver Diseases, Chicago, IL. November 4,
1998
26.
Anania F, Ehrinpreis MN: "Management of HCV infected patients with
compensated cirrhosis." Workshop and presentation at Amgen Clinical
Development Investigators Meeting. Maui, Hawaii. December 4, 1998.
27.
Siddiqui F, Naylor PH, Ehrinpreis MN, Peleman RR, Kinzie JL, Mutchnick MG:
Induction interferon treatment of African-Americans with hepatitis C results in an
enhanced response comparable to Caucasians given standard Interferon therapy.
Presented at Digestive Disease Week, Orlando, FL, May 17, 1999.
22
28.
Ullah N, Siddiqui FA, Naylor PH. Kinzie JL, Ehrinpreis M, Peleman RR,
Mutchnick MG,: Presence of hepatitis B virus core antibodies (Anti-HBC) in
chronic hepatitis C patients is predictive of a decreased end of treatment response
(ETR) to interferon. Presented at AASLD, Dallas, TX. November 6, 1999.
29.
Kinzie JL, Naylor PH, Ehrinpreis MN, Khan N, Siddiqui FA, Peleman
R R, Mutchnick MG. Reluctance of urban clinic patients to undergo treatment
with interferon-alpha. Presented at AASLD, Dallas, TX. November 6, 1999.
30.
Naylor PH, Brown KA, Gordon SC, Moonka D, Silverman AL, Kinzie JL,
Ehrinpreis MN, Peleman RR, Mutchnick MG: Response to retreatment with
interferon/ribavirin in Caucasian and African American relapsers and
nonresponders. Presented at AASLD, Dallas, TX. November 8,1999.
31.
Naylor PH, Kinzie JL, Ehrinpreis MN, Siddiqui F, Dhar R, Turner JR, Mutchnick
MG. Retreatment of interferon failures with combination therapy: log drop after 12
weeks of monotherapy predicts ETR to combination therapy. Presented at Tenth
International Symposium on Viral Hepatitis and Lime Disease, April 9-13, 2000,
Atlanta, GA
32.
Khalifa-Alsaleh A, Naylor PH, Kinzie JL, Ehrinpreis MN, Siddiqui F, Dhar R, Turner
JR, and Mutchnick MG.: End of treatment response (ETR) to Intron A
monotherapy in chronic hepatitis C is similar in patients with normal and elevated
ALT. Presented at 10th Int’l Symposium on Viral Hepatitis and Liver Disease,
Atlanta, GA, April 10, 2000
33.
Weidler N, Naylor PH Patel CM, Chilukuri S, Mendu S, Janisse JJ, Dhar R,
Ehrinpreis MN, Kinzie JL, Siddiqui F, Turner JR, Mutchnick MG.
Demographical and biochemical influences on quality of life scores in urban patients
with hepatitis C. Presented at DDW, San Diego, May 22, 2000.
34.
Kulkarni PM, Kinzie JL, Ehrinpreis MN. Argon plasma coagulator treatment in the
management of hematochezia secondary to chronic radiation proctopathy.
Presented at ACG Annual Scientific Meeting, New York, October 6-18, 2000.
35.
Ullah N, Yeh R, Ehrinpreis MN. Fatal hyperphosphatemia after oral phosphosoda preparation for colonoscopy: a case report and review of the literature.
Presented at ACG Annual Scientific Meeting, New York, October 16-18, 2000.
36.
Yeh R, Ullah N, Ehrinpreis MN. Role of lamivudine in the treatment of acute
hepatitis B infection associated with polyarteritis nodosa. Presented at ACG Annual
Scientific Meeting, New York, October 16-18, 2000
37.
Naylor PH, Meija L, Kinzie JL, Ehrinpreis MN, Dhar R, Siddiqui F, Turner JR,
Mutchnick MG. Tumor necrosis factor-a and chronic hepatitis C: low serum levels
in African Americans as compared to Caucasians. Presented at AASLD, Dallas,
10/29/00.
23
38.
Alawad G, Naylor PH, Hemacha A, Jamma K, Weidler N, Kinzie JL,
Ehrinpreis MN, Dhar R, Mutchnick MG.: Differences in side effect profiles
and response to combination ribavirin and interferon a2b (IFN) therapy
between Caucasians and African Americans with chronic hepatitis C.
Presented at AASLD, Dallas, 10/30/00.
39.
Siddiqui FA, Naylor PH, Ehrinpreis MN, Dhar R, Turner J, Murthy R, Kulkarni
P, Boag J, Mutchnick MG: Biochemical, histological and clinical
comparisons between African-American and Caucasian patients with
chronic hepatitis C in an urban clinic population. Presented at DDW, Atlanta,
5/21/2001.
40.
Khalifa A, Siddiqui F, Ehrinpreis M. A case of zinc toxicity due to massive
coin ingestion. Presented at the ACG Annual Scientific Meeting, Las Vegas,
10/23/2001.
41.
Siddiqui FA, Naylor P, Ehrinpreis M, Dhar R, Murthy R, Mutchnick M.
African-Americans with chronic hepatitis C respond poorly to interferon/ribavirin
combination treatment even when induction regimens are used. Presented at
DDW, San Francisco, 5/21/2002.
42.
Ehrinpreis MN. Gastrointestinal involvement in scleroderma. Presented at
Scleroderma Foundation National Conference, Las Vegas, 6/30/2002.
43.
Al-Subee O, Ehrinpreis M, Tyburski J. Pneumatosis coli associated with
cryptosporidiosis of the GI tract in AIDS patients. Presented at the ACG
Scientific Meeting, Seattle, 10/20/02.
Annual
44.
Zalewska I, Siddiqui F, Ehrinpreis M, Dhar R, Murthy R, Ranieri L, Janisse J,
Mutchnick M. African Americans failing treatment with interferon monotherapy for
chronic hepatitis C are less likely to achieve sustained response to subsequent
treatments compared to Caucasians. Presented at DDW, Orlando, 5/20/03.
45.
Pawa S, Ehrinpreis MN, Mutchnick MG, Dhar R, Siddiqui F. Percutaneous
liver biopsy in chronic hepatitis C patients with end stage liver disease.
Presented at DDW, New Orleans, 5/17/04.
46.
Duttala S, Al-Subee O, Ehrinpreis M. Retrospective analysis of patients
diagnosed with colorectal cancer above age of 75 by colonoscopy.
Presented at DDW, New Orleans, 5/19/04.
47.
Pawa S, Mutchnick M, Ehrinpreis M, Dhar R, Greer J, Siddiqui FA. Patients
with chronic hepatitis C and chronic renal insufficiency or end stage renal
disease respond poorly to interferon monotherapy. Presented at AASLD,
Boston, 10/30/04.
48.
Perez N, Ullah N, Tobi M, Wheeler D, Saksouk F, Ehrinpreis M. Fat or fiction:
ultrasound diagnosis of fatty liver in patients with chronic liver disease.
Presented at ACG Annual Meeting, Honolulu, 11/2/05.
24
49.
Perez N, Phillips C, Webber J, Ehrinpreis M. Jejunal obstruction caused by
an enterolith. Presented at ACG Annual Meeting, Honolulu, 10/31/05.
50.
Khan A, Mutchnick M, Ehrinpreis M, Dhar R, Siddiqui F. African-Americans
with Genotype-1 with Chronic Hepatitis C Respond Poorly to PegylatedInterferon and Ribavirin Combination Treatment as Compared to
Caucasians. Presented at ACG Annual Meeting, Honolulu, 10/30/05.
51.
Hammad H, Diez A, Perez N. Wiese W, Ehrinpreis, M. Hepatitis B flare after
cessation of HAART. Presented at ACG Annual Meeting, Las Vegas,
10/22/06.
52.
Pawa S, Greene M, Ehrinpreis, M. Ischemic colitis associated with epsilonaminocaproic acid therapy. Presented at ACG Annual Meeting, Las Vegas,
10/22/06.
53.
Maryala S, Perez N, Chandravanka C, Ehrinpreis M. Esophageal
actinomycosis. Presented at ACG Annual Meeting, Las Vegas, 10/22/06.
54.
Reyes P, Pawa S, Ehrinpreis M. Intestinal ganglioneuromatosis.
polyposis: a rare cause of abdominal pain. Presented at ACG Annual
Meeting, Las Vegas, 10/22/06.
55.
Pawa S, Ehrinpreis M, Mutchnick M, Dhar R, Janisse J, Siddiqui F. African
American and Caucasian patients with chronic hepatitis C genotype 2 or 3
respond similarly to interferon-based therapies. Presented at EASL Annual
Meeting, Barcelona, 4/2007.
56.
Hammad H, Perez N, Dahche T, Ehrinpreis M. GVHD of the GI tract after BMT:
are both upper and lower endoscopies necessary to make the diagnosis?
Presented at DDW, Washington, DC, 5/2007.
57.
Hammad H, Razumilava N, Perez N, Ehrinpreis M. Gastrointestinal bleeding
in biopsy-proven graft-versus-host disease of the GI tract: risk factors and
effect on mortality. Presented at ACG Annual Meeting, Philadelphia, 10/2007.
Invited Locally (Selected):
1.
Ehrinpreis, MN: "Nutritional Management of Hepatic Failure Patients." Presented
at Fourth Annual Parenteral and Enteral Nutrition Seminar, Michigan Inn,
Southfield, September 24, 1983.
2.
Ehrinpreis, MN: "Motor Disorders of the Esophagus." Presented at Michigan State
Medical Society Scientific Meeting, Hyatt Regency, Dearborn, November 16, 1983.
3.
Ehrinpreis, MN: "Options in Nutritional Support." Presented at Fifth Annual
Parenteral and Enteral Nutrition Seminar, Westin Hotel, Detroit, September 15,
1984.
25
4.
Ehrinpreis MN: "Update on Viral Hepatitis." Presented at Wayne State University
Continuing Medical Education "Update in Gastroenterology" seminar at Hyatt
Regency, Dearborn, February 26, 1986.
5.
Ahmad I, MN Ehrinpreis, A Narula, A Mehdiratta, J Kinzie, and E. Luby:
"Prolonged Small Intestinal Transit Time in Eating Disorder Patients." Presented
at ACP Regional Meeting, Traverse City, September 18, 1987.
6.
Parikh N and MN Ehrinpreis: "Esophageal Ulceration Due to Slow-released KCl in
a Patient With a Giant Left Atrium." Presented at ACP Regional Meeting, Traverse
City, September 17, 1987.
7.
Sofian-Conlan EJ, RR Peleman, K Surakomol, and MN Ehrinpreis: "Duodenal Bulb
Mucosal Bridge." Presented at ACP Regional Meeting, Traverse City, September
17, 1987.
8.
Ehrinpreis, MN: "Medical Therapy of Inflammatory Bowel Disease". Presented at
Michigan State Med. Society Scientific Meeting, Hyatt Regency, Dearborn,
November 11, 1987.
9.
Ehrinpreis, MN: "Treatment of Peptic Ulcer Disease." Presented at Medical Grand
Rounds, Holy Cross Hospital, November 17, 1987.
10.
Ehrinpreis MN: "When Should We Use GI Endoscopy?" Presented at Michigan
State Med. Society Scientific Meeting, Hyatt Regency, Dearborn, MI, November
10, 1988.
11.
Ehrinpreis MN: "Esophageal Disorders." Presented at Otolaryngology Grand
Rounds, Wayne State University, January 9, 1988.
12.
Ehrinpreis MN: "Peptic Ulcer Disease." Presented at Medical Grand Rounds, St.
Joseph Hospital, Pontiac, February 10, 1988.
13.
Ehrinpreis MN: "Nutritional Assessment." Presented at Medical Grand Rounds,
Harper Hospital, February 24, 1988.
14.
Ehrinpreis MN: "Diarrhea in the ICU." Presented at Critical Care Symposium,
Wayne State University, March 2, 1988.
15.
Ehrinpreis MN: "Management of the Malignant Polyp." Presented at Michigan
Society of Gastrointestinal Assistants, Detroit, October 8, 1988.
16.
Ehrinpreis MN: "Jaundice." Presented at Medical Grand Rounds, Holy Cross
Hospital, October 26, 1988.
17.
Parikh N, MN Ehrinpreis, C Conteas, and K Bergsman: "Upper Gastrointestinal
Hemorrhage from Metastatic Ovarian Carcinoma." Presented at ACP Regional
Meeting Traverse City, September 22, 1989.
26
18.
Ehrinpreis MN: "Peptic Ulcer Disease Management Update." Presented at
Michigan State Medical Society Scientific Meeting, Hyatt Regency, Dearborn,
Michigan
19.
Ehrinpreis MN: "Approach to Nutritional Support in Hospitalized Patients."
Presented at Family Medicine Grand Rounds, Holy Cross Hospital, February 8,
1989.
20.
Ehrinpreis MN: "Hepatic Ischemia." Presented at Medical Grand Rounds,
Harper Hospital, July 12, 1989.
21.
Ehrinpreis MN. "ABC (DE)'s of Viral Hepatitis." Presented at Michigan State
Medical Society Scientific Meeting, Hyatt Regency, Dearborn, MI, November 8,
1990.
22.
Ehrinpreis MN: "Peptic Ulcer Disease." Presented at Sanilac County Medical
Society, Marlette, MI, January 9, 1990.
23.
Ehrinpreis MN: "A Patient With Cholestasis." Presented at CPC, Harper Hospital,
October 3, 1990.
24.
Ehrinpreis MN: "Pathophysiology and treatment of Peptic Ulcer Disease" and
"NSAID-Induced Gastropathy." Presented at Bon Secour Hospital, Visiting
Professor, Grosse Pointe, MI, September 13, 1990.
25.
Ehrinpreis MN: "Hepatobiliary Abnormalities and TPN." Presented at Michigan
Society for Parenteral and Enteral Nutrition Annual Meeting, Traverse City, MI,
September 21, 1991.
26.
Shafiuddin M, Reddy J, and Ehrinpreis MN: "Salmonella Mycotic Aneurysm of the
Common Iliac Artery Masquerading as a Pelvic Abscess." Presented at ACP
Regional Meeting, Traverse City, September 1991.
27.
Barbish AW and Ehrinpreis MN: "Successful Sclerotherapy of Bleeding Duodenal
Varices." Presented at ACP Regional Meeting, Traverse City, September 1991.
28.
Ehrinpreis MN: Candida-induced, antibiotic-associated diarrhea". Presented at GI
Grand Rounds. Beaumont Hospital, Royal Oak, MI, April 2, 1991.
29.
Meyerson S, Polidori G, Yang S, Peleman R, Ehrinpreis M, Goo R, and Kinzie J:
"Our Initial Experience With Endoscopic Esophageal Varix Ligation." Presented at
ACP Regional Meeting. Traverse City, October 3, 1992.
30.
Ehrinpreis MN: "Chronic Gastritis." Presented at Medical Grand Rounds, Grace
Hospital, Detroit, MI, April 2, 1992.
31.
Ehrinpreis MN: "Hepatobiliary Abnormalities and TPN." Presented at American
Society for Parenteral and Enteral Nutrition regional course. Ritz Carlton Hotel,
Dearborn, MI, May 28, 1992.
27
32.
Ehrinpreis MN: "Pathogenesis of Hepatic Inflammation." Presented at Wayne
State University Symposium on Chronic Viral Hepatitis, Mackinac Island, MI,
September 11, 1992.
33.
Ehrinpreis MN: "Helicobacter pylori, Infection." Presented at Medical Ground
Rounds, Harper Hospital, Detroit, MI, November 10, 1993.
34.
Ehrinpreis MN: "Whipple's Disease", presented at Clinical-Pathological
Conference, Detroit, MI, March 23, 1994.
35.
Ehrinpreis MN: "Malabsorption", presented at 14th Annual OHEP Intesine Internal
Medicine Review, Northfield Hilton, Troy, MI, June 9, 1994.
36.
Ehrinpreis MN: "Helicobater Update - When and How to Treat", presented at
Update in Gastroenterology, Holy Cross Hospital, Detroit, Michigan, August 31,
1994.
37.
Ehrinpreis MN: "Infectious Diseases of the Upper G.I. Tract", presented at Wayne
State University Symposium on Gastroenterology Advances: The Upper GI Tract,
on, Mackinac Island, Michigan, September 8-11, 1994.
38.
Ehrinpreis MN: "Nutritional Support-Progress & Problems", presented at
Gastroenterology Course, Bon Secours Hospital, Grosse Pointe, Michigan,
October 6, 1994.
39.
Ehrinpreis MN: "Drug-Induced Liver Disease", presented at Medicine Subspecialty
Conference, Oakwood Hospital, Dearborn, Michigan, February 7, 1995.
40.
Ehrinpreis MN: "Esophageal Infections" Academic Workshop Leader, Michigan
Regional G.I. Consultants Conference, Traverse City, Michigan, March 31 - April 2,
1995.
41.
Ehrinpreis MN: "Diagnosis and Management of PUD and Esophagitis", presented
at 15th Annual OHEP Internal Medicine Review, Northfield Hilton, Troy, Michigan,
June 8, 1995.
42.
Ehrinpreis MN: "Update on Pancreatitis", presented at Holy Cross Hospital GI
Symposium, Detroit, MI, August 3, 1995.
43.
Ehrinpreis MN: "Acute Pancreatitis", presented at Providence Hospital Medical
Grand Rounds, Southfield, MI, October 26, 1995.
44.
Ehrinpreis MN: "Implications of Helicobacter pylori Infection", Federal Pharmacists
Association Continuing Education, Ann Arbor, MI, January 25, 1996.
45.
Ehrinpreis MN: "Helicobacter pylori", Oakwood Hospital, Dearborn, Michigan,
March 6, 1996.
46.
Ehrinpreis MN: "Helicobacter pylori", Riverside Osteopathic Hospital, Trenton,
Michigan, March 7, 1996.
28
47.
Ehrinpreis MN: “Peptic Ulcer Disease and Esophagitits”, presented at 16th Annual
OHEP Internal Medicine Review, Northfield Hilton, Troy, MI, June 13, 1996.
48.
Ehrinpreis MN: “Advances in Total Parenteral Nutrition”, presented at the Update
in Gastroenterology, Holy Cross Hospital, Detrioit, MI, October 30, 1996.
49.
Ehrinpreis MN: “Drug Induced Hepatitis”, presented at Liver Disease Symposium,
Macomb Hospital Center, Warren, MI, November 2, 1996.
50.
Ehrinpreis MN: “Approach to GERD and PUD”, presented at Wayne State
University Gastroenterology Conference Special Lecture for OHEP Save 100
program, Detroit, MI, February 19, 1997.
51.
Ehrinpreis MN: “Peptic Ulcer Disease and Esophagtitis” presented at 17th Annual
OHEP Internal Medicine Review, Northfield Hilton, Troy, MI, June 15, 1997.
52.
Ehrinpreis MN: ACG Regional Postgraduate Course, Director and Moderator,
Ypsilanti Marriott, Ypsilanti, MI, June 21-22, 1997.
53.
Ehrinpreis MN: “Helicobacter pylori Update” presented at 4th Annual
Gastroenterology Symposium, Holy Cross Hospital, Detroit, MI, August 27, 1997.
54.
Ehrinpreis MN: “Post-radiation Rectal Bleeding” presented at Symposium on
Prostate Cancer, Karmanos Cancer Institute, Bloomfield Hills, MI, October 4, 1997.
55.
Ehrinpreis MN: “Emergencies in Regional Enteritis”, presented at Wayne State
University Emergency Medicine Grand Rounds, Detroit Receiving Hospital, Detroit,
MI, October 23, 1997.
56.
Ehrinpreis MN: “Refractory Ascites,” presented at Gastroenterology & Hepatology:
Advances in Diagnosis and Treatment. Mackinac Island, MI. September 11, 1998
.
57.
58.
Ehrinpreis MN: "Update on Inflammatory Bowel Disease," presented at Medical
Grand Rounds, Wayne State University, Veterans Affairs Hospital, Detroit, MI,
January 20, 1999.
Ehrinpreis MN: "Update on Pancreatitis," presented at Medical Grand Rounds
Oakwood Hospital, Dearborn, MI. March 25, 1999.
59.
Ehrinpreis MN: “Idiopathic Inflammatory Bowel Disease,” presented at 18th
annual OHEP Internal Medicine Review, Northfield Hilton, Troy, MI, June 10,
1999.
60.
Ehrinpreis MN: "Future of Acid Suppression," presented at Medical Grand
Rounds, Memorial Medical Center, Ludington, MI. August 24, 1999.
61.
Ehrinpreis MN: "Treatment of Chronic Hepatitis C," presented at Perspectives
on Hepatitis B & C for the Primary Care Physician, Novi Hilton, Novi, MI October
30,1999.
29
62.
Ehrinpreis MN: "Update on Hepatitis C," presented at the Phillipine Medical
Association Meeting, Westin, Southfield, MI. April 15, 2000.
63.
Ehrinpreis MN: "Inflammatory Bowel Disease," presented at 2000 OHEP
Intensive Internal Medicine Board Review, Northfield Hilton, Troy, MI, June
8, 2000.
64.
Ehrinpreis MN: "Enteral Nutrition, Including PEG-tube Feeding, " 7th Annual
Gastroenterology Symposium, St. John North East Community Hospital,
Detroit, MI, September 27, 2000.
65.
Ehrinpreis MN: “Inflammatory Bowel Disease,” presented at 2001 OHEP
Intensive Internal Medicine Board Review, Northfield Hilton, Troy, MI, June
14, 2001.
66.
Ehrinpreis MN: "Helicobacter pylori Update including MALT
Lymphoma, " 8th Annual Gastroenterology Symposium, St. John North East
Community Hospital, Detroit, MI, September 26, 2001.
67.
Ehrinpreis MN: “Inflammatory Bowel Disease,” presented at 2002 OHEP
Intensive Internal Medicine Board Review, Northfield Hilton, Troy, MI, June
6, 2002.
68.
Ehrinpreis MN: “Gastrointestinal Problems in Scleroderma,” presented at
Michigan Scleroderma Foundation Regional Meeting, Troy Marriott, Troy,
MI, September 22, 2002.
69.
Ehrinpreis MN: “Evaluation of Chronic Diarrhea,” presented at 9th Annual
Gastroenterology Symposium, St. John North East Community Hospital,
Detroit,
MI, September 25, 2002.
70.
Ehrinpreis MN: “Update on Endoscopy: Video Capsule Endoscopy,”
presented at Medical Grand Rounds, Wayne State University, Detroit, MI,
February 12, 2003.
71.
Ehrinpreis MN: “Inflammatory Bowel Disease,” presented at 2003 OHEP
Intensive Internal Medicine Board Review, Beverly Hills, MI, June 5, 2003.
72.
Ehrinpreis MN: “CPC: Developing GI Catastrophe,” presented at Medical Grand
Rounds, Sinai-Grace Hospital, Detroit, MI, October 23, 2003.
73.
Ehrinpreis, MN: “Wireless Capsule Endoscopy,” presented at Wayne State
University Surgical Grand Rounds, Harper University Hospital, Detroit, MI,
November 5, 2003.
74.
Ehrinpreis MN: “Obscure Gastrointestinal Bleeding,” presented at
Gastroenterology and Hepatology: Advances in Diagnosis and Treatment,
Mackinac Island, MI, September 11, 2004.
30
75.
Ehrinpreis MN: “Video Capsule Endoscopy,” presented at
Gastroenterology and Hepatology: Advances in Diagnosis and Treatment,
Mackinac Island, MI, September 11, 2004.
76.
Ehrinpreis MN: “Decision Making Related to Alternative Modes of Nutrition,”
presented at Ethics and Dysphagia, Rehabilitation Institute of Michigan,
Detroit, October 9, 2004.
77.
Ehrinpreis MN: “Inflammatory Bowel Disease,” “Esophageal Disorders,”
“‘Camera Pill’-Video Endoscopy,” presented at 5th Annual Update in Internal
Medicine, Bay Harbor, MI, July 31, 2005.